Very few studies have evaluated transjugular intrahepatic portosystemic shunt (TIPS) insertion in liver transplant recipients. In general, it appears to be a viable long-term treatment option in some patients and may serve as a bridge to retransplantation in others. The overall risk of early mortality appears to be similar to patients without transplants; mortality is more common in patients with advanced liver and kidney disease.
SUGGESTED READINGS
1
Ferral H, Gamboa P, Postoak D W et al..
Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score.
Radiology.
2004;
231
231-236
2
Harrod-Kim P, Saad W, Waldman D.
Predictors of early mortality after transjugular intrahepatic portosystemic shunt creation for the treatment of refractory ascites.
J Vasc Interv Radiol.
2006;
17
1605-1610
3
Patel N H, Patel J, Behrens G, Savo A.
Transjugular intrahepatic portosystemic shunts in liver transplant recipients: technical considerations and review of the literature.
Semin Intervent Radiol.
2005;
22
329-333
5
Russo M W, Sood A, Jacobson I M, Brown Jr R S.
Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality.
Am J Gastroenterol.
2003;
98
2521-2527
6
Van Ha T G, Funaki B S, Ehrhardt J et al..
Transjugular intrahepatic portosystemic shunt placement in liver transplant recipients: experiences with pediatric and adult patients.
AJR Am J Roentgenol.
2005;
184
920-925